Vaccinations can significantly help reduce the severity of COVID-19 . However, global reports of breakthrough infections and reinfections raise the need for an adjunct that can confer additional, improved inflammatory immune response. Curcumin, a polyphenol, reduces levels of inflammatory cytokines and chemokines by targeting multiple proinflammatory pathways.
Although it is safe and well-tolerated in high doses, it shows poor bioavailability and is rapidly degraded. To overcome these limitations, a new curcumin formulation (CURC) was compared with a placebo for its effects on circulating inflammatory biomarkers in 31 adults who had recovered from COVID-19 and received a primary series of monovalent vaccine doses. CURC twice a day for four weeks caused a significant reduction in proinflammatory interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) relative to the placebo…
